Evommune, Inc.

Healthcare

NYSE:EVMN · New York Stock Exchange

Market Cap $292.49M Beta 0.10 P/E (TTM) -9.1

$21.36 -0.82%

-$0.17 today

52W Low $13.89High $33.20

Vol 0.48M · Avg 0.38M

EPS (TTM) -$2.26Biotechnology

Management

Put operating results in leadership context

Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-33.5%

avg 18.9%

ROIC

-39.0%

avg -77.1%

ROA

-30.6%

avg -53.3%

Analysis

ROA is currently the strongest return metric at -30.6% versus its period average of -53.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Management

Key executives, compensation & ownership

Management

Name	Title	Compensation	Tenure	Age	Shares Owned	Ownership %
Luis C. Pena	Founder, President, Chief Executive Officer & Director	$1.33M	—	63	—	—
Gregory S. Moss	Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer	$1.03M	—	42	—	—
Kyle Carver	Chief Financial Officer	$1.01M	—	38	—	—
Daniel J. Burge	Senior Vice President of Clinical Development	—	—	64	—	—
J. Mark Jackson	Senior Vice President of Clinical Development	—	—	—	—	—
Jeegar Patel	Chief Scientific Officer	—	—	48	—	—
Janice Drew	Chief of Development Operations	—	—	63	—	—
Eugene Andrew Bauer	Co-Founder, Chief Medical Officer & Director	—	—	84	—	—
Lou Sehl	Senior Vice President of Technical Operations	—	—	—	—	—